Year |
Citation |
Score |
2019 |
Miodragović Đ, Merlino A, Swindell EP, Bogachkov A, Ahn RW, Abuhadba S, Ferraro G, Marzo T, Mazar AP, Messori L, O'Halloran TV. Arsenoplatin-1 is a Dual Pharmacophore Anti-Cancer Agent. Journal of the American Chemical Society. PMID 30943017 DOI: 10.1021/Jacs.8B13681 |
0.598 |
|
2014 |
Xu X, Cai Y, Wei Y, Donate F, Juarez J, Parry G, Chen L, Meehan EJ, Ahn RW, Ugolkov A, Dubrovskyi O, O'Halloran TV, Huang M, Mazar AP. Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM). Plos One. 9: e85349. PMID 24465541 DOI: 10.1371/Journal.Pone.0085349 |
0.56 |
|
2013 |
Hong BJ, Swindell EP, Macrenaris KW, Hankins PL, Chipre AJ, Mastarone DJ, Ahn RW, Meade TJ, O'Halloran TV, Nguyen ST. pH-Responsive Theranostic Polymer-Caged Nanobins (PCNs): Enhanced Cytotoxicity and T 1 MRI Contrast by Her2-Targeting. Particle & Particle Systems Characterization : Measurement and Description of Particle Properties and Behavior in Powders and Other Disperse Systems. 30: 770-774. PMID 24516291 DOI: 10.1002/Ppsc.201300158 |
0.522 |
|
2013 |
Zhang Y, Kenny HA, Swindell EP, Mitra AK, Hankins PL, Ahn RW, Gwin K, Mazar AP, O'Halloran TV, Lengyel E. Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy. Molecular Cancer Therapeutics. 12: 2628-39. PMID 24061648 DOI: 10.1158/1535-7163.Mct-13-0204 |
0.621 |
|
2013 |
Miodragović ÄU, Quentzel JA, Kurutz JW, Stern CL, Ahn RW, Kandela I, Mazar A, O'Halloran TV. Robust structure and reactivity of aqueous arsenous acid-platinum(II) anticancer complexes. Angewandte Chemie (International Ed. in English). 52: 10749-52. PMID 24038962 DOI: 10.1002/Anie.201303251 |
0.532 |
|
2013 |
O'Halloran TV, Ahn R, Hankins P, Swindell E, Mazar AP. The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target. Theranostics. 3: 496-506. PMID 23843897 DOI: 10.7150/Thno.4953 |
0.617 |
|
2013 |
Ahn RW, Barrett SL, Raja MR, Jozefik JK, Spaho L, Chen H, Bally MB, Mazar AP, Avram MJ, Winter JN, Gordon LI, Shea LD, O'Halloran TV, Woodruff TK. Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo. Plos One. 8: e58491. PMID 23526987 DOI: 10.1371/Journal.Pone.0058491 |
0.747 |
|
2012 |
Zhang Y, Swindell EP, Ahn RW, Mitra A, Mazar AP, O'Halloran TV, Kenny HA, Lengyel E. Abstract 2885: Urokinase plasminogen activator system targeted delivery of arsenic trioxide loaded nanobins as a novel ovarian cancer therapeutic Cancer Research. 72: 2885-2885. DOI: 10.1158/1538-7445.Am2012-2885 |
0.644 |
|
2011 |
Mazar AP, Ahn RW, O'Halloran TV. Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic. Current Pharmaceutical Design. 17: 1970-8. PMID 21711234 DOI: 10.2174/138161211796718152 |
0.597 |
|
2011 |
Kim AM, Bernhardt ML, Kong BY, Ahn RW, Vogt S, Woodruff TK, O'Halloran TV. Zinc sparks are triggered by fertilization and facilitate cell cycle resumption in mammalian eggs. Acs Chemical Biology. 6: 716-23. PMID 21526836 DOI: 10.1021/Cb200084Y |
0.654 |
|
2011 |
Ahn RW, Swindell EP, Doan NB, Ugolkov A, Malin D, Raja MR, Mazar AP, Cryns VL, O'Halloran TV. Abstract LB-202: Therapeutic efficacy of coencapsulated cisplatin and arsenic trioxide nanobins in murine models of breast cancer Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-202 |
0.749 |
|
2010 |
Lee SM, Ahn RW, Chen F, Fought AJ, O'Halloran TV, Cryns VL, Nguyen ST. Biological evaluation of pH-responsive polymer-caged nanobins for breast cancer therapy. Acs Nano. 4: 4971-8. PMID 20738118 DOI: 10.1021/Nn100560P |
0.648 |
|
2010 |
Ahn RW, Chen F, Chen H, Stern ST, Clogston JD, Patri AK, Raja MR, Swindell EP, Parimi V, Cryns VL, O'Halloran TV. A novel nanoparticulate formulation of arsenic trioxide with enhanced therapeutic efficacy in a murine model of breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 3607-17. PMID 20519360 DOI: 10.1158/1078-0432.Ccr-10-0068 |
0.742 |
|
2010 |
Barrett SL, Ahn RW, Raja MR, Jozefik JK, Spaho L, Chen H, Bally M, Avram MJ, Gordon LI, Shea LD, O'Halloran TV, Woodruff TK. In Vitro Risk Assessment of a Nanoparticulate Formulation of Arsenic Trioxide in Isolated Ovarian Follicles Is Representative of Effects In Vivo. Biology of Reproduction. 83: 298-298. DOI: 10.1093/Biolreprod/83.S1.298 |
0.703 |
|
2010 |
Tenchov BG, Koynova R, Ahn RW, O'Halloran TV, MacDonald RC. Stability of oligodeoxynucleotide complexes with cationic phospholipid and peptide carriers Nanotechnology 2010: Bio Sensors, Instruments, Medical, Environment and Energy - Technical Proceedings of the 2010 Nsti Nanotechnology Conference and Expo, Nsti-Nanotech 2010. 3: 342-345. |
0.407 |
|
2009 |
Chen H, Pazicni S, Krett NL, Ahn RW, Penner-Hahn JE, Rosen ST, O'Halloran TV. Coencapsulation of arsenic- and platinum-based drugs for targeted cancer treatment. Angewandte Chemie (International Ed. in English). 48: 9295-9. PMID 19894238 DOI: 10.1002/Anie.200903655 |
0.633 |
|
2009 |
You EA, Ahn RW, Lee MH, Raja MR, O'Halloran TV, Odom TW. Size control of arsenic trioxide nanocrystals grown in nanowells. Journal of the American Chemical Society. 131: 10863-5. PMID 19624123 DOI: 10.1021/Ja902117B |
0.707 |
|
2009 |
Chen H, Ahn R, Van den Bossche J, Thompson DH, O'Halloran TV. Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Molecular Cancer Therapeutics. 8: 1955-63. PMID 19567824 DOI: 10.1158/1535-7163.Mct-09-0045 |
0.629 |
|
2008 |
Winter JN, Waterhouse D, Ahn R, Chen H, Gordon LI, Jovanovic B, Bally M, O’Halloran T. Triggered Release of Nanoparticulate Arsenic Trioxide for Treatment of Malignant Lymphomas: Preclinical Studies Blood. 112: 4989-4989. DOI: 10.1182/Blood.V112.11.4989.4989 |
0.393 |
|
Show low-probability matches. |